EUVIMEDEUVIMED entdecken
Crossref

Targeting IKZF1 via HDAC1: Combating Acute Myeloid Leukemia

Sathyanarayan Balaji iD, Suvitha Anbarasu iD, Sudha Ramaiah iD, Anand Anbarasu iD

Integrative Biology · 23.01.2024 · 16

DOI: 10.1093/intbio/zyae022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Integrative Biology, online erschienen am 16.12.2024. Verfasst von Sathyanarayan Balaji und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore District, Tamil Nadu State, 6…. Hauptthemen laut MEDLINE: Histone Deacetylase 1, Leukemia, Myeloid, Acute, Ikaros Transcription Factor, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) accounts for 1.3% of all cancers, with a limited survival of only 30%, and treating AML is a continuous challenge in medicine. IKZF1 is a DNA-binding protein that is highly mutated and undruggable but significant in causing AML. The current study aims to target its transcription factors (TFs) modulating IKZF1 activity. The TF network was constructed and analyzed which revealed a dense Markov cluster (MCL) cluster and five hub genes namely, HDAC1, EP300, CREBBP, TP53, and MYC; the first node clusters were generated for the hub genes. Functional enrichment analysis found AML pathway enriched in all the clusters. Gene ontology terms were majorly related to transcription regulation terms including RNA polymerase transcription regulation, DNA binding activity, DNA templated transcription, and transcription factor binding. Further, the mutation profile of all the TFs found HDAC1 with a very low mutation profile of 0.1% and the survival plot found HDAC1 with a hazard ratio of 1.17 with increased survival upon low expression. Also, among the hub genes, HDAC1 was the only first node interactor with IKZF1. Thus, HDAC1 could be a potential biomarker candidate as well as a key target in treating AML. Insight Box The study has an integrated approach for identifying a potential target through network analysis, functional enrichment analysis, mutation profiling survival prognosis, and target screening. The study employs a better strategy for targeting IKZF1, a significantly upregulated gene in AML by regulating its transcription factors. The analysis revealed a network of TFs regulating IKZF1, among which HDAC1 emerged as a promising candidate due to its low mutation rate, association with better survival outcomes, and direct interaction with IKZF1. This suggests HDAC1 could be a valuable biomarker and therapeutic target for AML treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase 1Leukemia, Myeloid, AcuteIkaros Transcription FactorMutationHumansGene Regulatory NetworksTranscription FactorsGene Expression Regulation, LeukemicProtein Interaction Maps

Stichwörter der Autor:innen

enrichment analysismutational profilingnetwork analysissurvival analysistranscription factorszinc finger protein

Substanzen

Histone Deacetylase 1HDAC1 protein, humanIKZF1 protein, humanIkaros Transcription FactorTranscription Factors

Autor:innen und Institutionen

  • Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore District, Tamil Nadu State, 632014, India.
  • Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore District, Tamil Nadu State, 632014, India.
  • Department of Biosciences, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore District, Tamil Nadu State, 632014, India.

ORCID-Profile: Sathyanarayan Balaji, Suvitha Anbarasu, Sudha Ramaiah, Anand Anbarasu

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Balaji, S., Anbarasu, S., Ramaiah, S., & Anbarasu, A. (2024). Targeting IKZF1 via HDAC1: Combating Acute Myeloid Leukemia. Integrative Biology, 16. https://doi.org/10.1093/intbio/zyae022

Vancouver

Balaji S, Anbarasu S, Ramaiah S, Anbarasu A. Targeting IKZF1 via HDAC1: Combating Acute Myeloid Leukemia. Integrative Biology. 2024;16. doi:10.1093/intbio/zyae022

BibTeX
@article{Balaji2024,
  author = {Balaji, Sathyanarayan and Anbarasu, Suvitha and Ramaiah, Sudha and Anbarasu, Anand},
  title = {Targeting IKZF1 via HDAC1: Combating Acute Myeloid Leukemia},
  journal = {Integrative Biology},
  year = {2024},
  volume = {16},
  doi = {10.1093/intbio/zyae022}
}
Kostenlos starten →